Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: Intravascular ultrasound results from ENDEAVOR III
| Autor: | David E. Kandzari, Ichizo Tsujino, Brian K. Courtney, Junya Ako, Yasuhiro Honda, Ali Hassan, Akiyoshi Miyazawa, Yoichiro Hongo, Peter J. Fitzgerald, Seung Ho Hur |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty Time Factors medicine.medical_treatment Risk Assessment Sensitivity and Specificity Coronary Restenosis Reference Values Internal medicine Intravascular ultrasound Coronary stent Humans Medicine Single-Blind Method Zotarolimus cardiovascular diseases Angioplasty Balloon Coronary Ultrasonography Interventional Vascular Patency Aged Probability Sirolimus Neointimal hyperplasia medicine.diagnostic_test business.industry Coronary Stenosis Stent Drug-Eluting Stents Middle Aged equipment and supplies medicine.disease Survival Rate Treatment Outcome surgical procedures operative medicine.anatomical_structure Drug-eluting stent Circulatory system Cardiology Female Tunica Intima Cardiology and Cardiovascular Medicine business Follow-Up Studies Artery medicine.drug |
| Zdroj: | American Heart Journal. 155:108-113 |
| ISSN: | 0002-8703 |
| Popis: | The purpose of this study was to investigate the vascular response of zotarolimus-eluting stent (ZES) and sirolimus-eluting stent (SES) using serial intravascular ultrasound (IVUS).Data were obtained from the Endeavor Drug-Eluting Coronary Stent System Versus the Center Siromlimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ENDEAVOR) III trial, a randomized study comparing ZES and SES for the treatment of de novo native coronary artery lesions. Serial (baseline and 8-month follow-up) IVUS was available in 258 patients (190 ZES, 68 SES).At 8 months, ZES had greater percentage of neointimal volume index (ZES 1.1 +/- 0.8 mm3/mm vs SES 0.2 +/- 0.1 mm3/mm, P.01), resulting in smaller lumen volume index (6.0 +/- 2.0 mm3/mm vs 7.0 +/- 2.1 mm3/mm, P.05). Zotarolimus-eluting stents showed larger IVUS-detectable neointimal coverage over stent surface (50.2% vs 10.5%, P.01) and greater mean neointimal thickness (0.19 +/- 0.07 mm vs 0.10 +/- 0.06 mm, P.01). Zotarolimus-eluting stents had a significantly lower incidence of late-acquired incomplete stent apposition.Zotarolimus-eluting stent is associated with a significantly greater amount of neointimal hyperplasia compared with SES. This amount of hyperplasia in ZES is distributed throughout the stent at 8-month follow-up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect